Zhen Su, M.D.Senior Vice President, Head of Global Oncology Franchise at Merck KGaA Darmstadt Germany
Zhen Su, M.D. is the Senior Vice President and Chief Medical Officer of EMD Serono, North America. He leads medical strategy for all products in North America and drives execution of key medical initiatives focusing on improving patient outcomes in key therapeutic areas, including Neurology, Immunology, Oncology, Fertility, and Endocrinology. A physician executive with nearly 20 years of experience, Dr. Su has strong clinical expertise in Oncology, Urology, and Immuno-Oncology.
Dr. Su joined EMD Serono in 2015 as the Vice President and Head of US Medical Affairs for Oncology, and successfully built an Oncology Medical Affairs team from the ground up. The team effectively supported the global launch of BAVENCIO® (avelumab) and the co-promotion of XALKORI® (crizotinib) in the US and Canada through the strategic alliance between EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer. More recently, Dr. Su was appointed as Global Head of Medical Affairs Oncology, leading Medical Affairs activities to support the market leadership of ERBITUX® (cetuximab) (outside the US and Canada), global BAVENCIO launches and acceleration of the oncology pipeline.
He has held positions in academia and pharmaceutical medicine with roles of increasing responsibilities, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served as Associate Vice President and Global Head of JEVTANA® (cabazitaxel) at Sanofi and Country Medical Director for GSK in Canada. Prior to joining industry, Dr. Su held several academic positions, including Assistant Professor at Duke University Medical Center, where he also received his post-doctoral fellowship in Genitourinary Oncology. He then served as Assistant Professor and Cancer Immunotherapy Program Director at the University of Florida.
Dr. Su has deep ties to the oncology and immunology communities, having worked with leading oncologists at organizations across the globe. Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.